Ani Pharmaceuticals (ANIP) Research & Development (2010 - 2026)

Ani Pharmaceuticals has disclosed Research & Development across 17 years of filings, most recently posting $10.6 million for Q1 2026.

• Research & Development for Q1 2026 came in at $10.6 million, changed 0.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.7 million (up 15.83% YoY), and the FY2025 annual result was $51.7 million, up 15.89% from the prior year.
• Research & Development came in at $10.6 million for Q1 2026 at Ani Pharmaceuticals, down from $12.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $16.6 million in Q4 2024 to a low of $4.2 million in Q2 2022.
• The 5-year median for Research & Development is $10.1 million (2024), against an average of $9.6 million.
• Across the five-year window, Research & Development soared 211.77% in 2022 and retreated 26.34% in 2025, its largest moves.
• Ani Pharmaceuticals' Research & Development stood at $5.2 million in 2022, then surged by 88.95% to $9.9 million in 2023, then jumped by 68.7% to $16.6 million in 2024, then retreated by 26.34% to $12.3 million in 2025, then dropped by 13.55% to $10.6 million in 2026.
• The last three Research & Development figures came in at $10.6 million (Q1 2026), $12.3 million (Q4 2025), and $12.3 million (Q3 2025), per Business Quant data.